November 11, 2021 News by Marisa Wexler, MS sNfL Levels Linked to Relapse-free Disability Progression, Move to SPMS Measuring levels of the protein serum neurofilament light chain (NfL)Ā can help to identify people with relapsing-remitting multiple sclerosis (RRMS) at higher risk of relapse-free disability progression or conversion to secondary-progressive disease, according to a study from Germany. The study, “NfL predicts relapse-free progression in a longitudinal…
September 7, 2021 News by Yedida Y Bogachkov PhD Brain Atrophy, Serum NfL Levels May Predict Cognition Early in MS A blood test for serum neurofilament light chain (sNfL) levels, along with radiological findings, can help to detect early cognitive issues in people recently diagnosed with multiple sclerosis (MS), a study suggests. The study āCortical Thickness and Serum NfL Explain Cognitive Dysfunction in Newly Diagnosed Patients…
January 19, 2021 News by Marta Figueiredo, PhD Ocrevus Targets Pro-inflammatory T-cells, Not Just B-cells, in PPMS, Study Finds In addition to significantly reducing subsets of B-cells ā its main immune cell target ā Ocrevus (ocrelizumab) lessens pro-inflammatory immune T-cells in people with primary progressiveĀ multiple sclerosis (PPMS), a small study shows. Notably, the suppression of immune cell subsets thought to be involved in the abnormal immune responses…
October 12, 2020 News by Sara Guariglia Metabolic Changes Relating to MS Onset, Progression Focus of Study A $957,000 grant will support research at the University at BuffaloĀ intoĀ events that precede the onset of neurodegeneration inĀ multiple sclerosis (MS). Specifically, the funding byĀ the U.S. Army Medical Research and Development CommandĀ will be used to investigate possible changes in cell metabolism that lead toĀ disease onset or progression in…
September 11, 2019 News by Patricia Inacio, PhD #ECTRIMS2019 – Real-world Data Supports Serum Neurofilament Light as Potential MS Biomarker Serum neurofilament light chain (sNfL) in the blood ā a proposed biomarker for multiple sclerosis (MS) ā is linked with worse neurologic function at levels above a certain threshold, according to data from a large, real-world study. Kathryn Fitzgerald, assistant professor at the Johns Hopkins School of…
June 19, 2019 News by Patricia Inacio, PhD Lemtrada Lowers Levels of Nerve Damage Biomarker Better Than Rebif, Trial Data Show Treatment with Sanofi GenzymeāsĀ LemtradaĀ (alemtuzumab) for up to two years lowers the levels of serum neurofilament light chain (sNfL), a proposed biomarker of nerve damage, in relapsing-remitting multiple sclerosisĀ (RRMS) patients to levels comparable to those seen in healthy people, data from the CARE-MS I study shows. Lemtradaās effectiveness…
October 17, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 – Serum Neurofilament Light Show Promise as Biomarker, But Not There Yet, Neurologists Say Despite its lack of specificity to multiple sclerosis (MS) in particular, monitoring patients with a blood biomarker ā serum neurofilament light (sNfL) ā may hold promise as a relatively easy way to assess treatment response and brain damage, according to MS experts. But there’s considerable work still to be…
April 18, 2018 News by Alice MelĆ£o, MSc #AAN2018 ā Levels of Protein Derived from Brain Cell Damage Can Mirror Severity of MS, Study Finds Levels of a protein stemming from brain cell damage can mirror the severity and symptoms of multiple sclerosis, an analysis of combined data from three trials showed. Researchers will present this and related findingsĀ at the annual meeting of the American Academy of NeurologyĀ in Los Angeles, April 21-27. The…